Abilify

Generic Name

Aripiprazole.

Drug Class

Atypical antipsychotics.

Formulation

Abilify is available in oral tablets, orally disintegrating tablets, oral solution, and intramuscular injection forms.

Uses

Abilify is used to treat schizophrenia, bipolar I disorder, major depressive disorder, irritability associated with autistic disorder, and Tourette’s disorder in both adolescents and adults. It is also approved for adjunctive treatment of major depressive disorder.

Dosage Information

The dosage of Abilify varies based on the condition treated. For schizophrenia, the starting dose is usually 10-15 mg/day, with a target dosage of 10-30 mg/day. For bipolar disorder, the initial dose is 15 mg/day as monotherapy or adjunctive therapy. Doses for the treatment of major depressive disorder start at 2-5 mg/day, adjusting to a target dose of 5-15 mg/day. Dosage must be tailored to individual needs and response.

Administration

Abilify can be taken with or without food. Oral tablets should not be split, crushed, or chewed. Orally disintegrating tablets should be handled with dry hands. Ensure injection is administered by a healthcare professional.

Mechanism of Action

Abilify works by modulating dopamine and serotonin receptors in the brain, particularly as a partial agonist at the D2 and 5-HT1A receptors and as an antagonist at 5-HT2A receptors. This results in a balance of neurotransmitters crucial for mood and behavior stabilization.

Side Effects

Common side effects of Abilify include headache, nausea, vomiting, constipation, agitation, anxiety, insomnia, and weight gain. Serious side effects may include tardive dyskinesia, neuroleptic malignant syndrome, seizure, and risk of suicidal thoughts and behaviors, particularly in young adults.

Contraindications

Abilify is contraindicated in individuals with known hypersensitivity to aripiprazole or any of the product excipients. This includes severe reactions like anaphylaxis and angioedema.

Interactions

Abilify may interact with various drugs including antihypertensives, as it can enhance the hypotensive effect. It can also interact with CNS depressants, potentially increasing sedation. Additionally, inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., fluoxetine) can increase aripiprazole levels, while CYP3A4 inducers (e.g., carbamazepine) can decrease its levels.

Special Populations

In elderly patients with dementia-related psychosis, Abilify has an increased risk of death. It should be used cautiously in pregnant or breastfeeding women, as it can be excreted in breast milk and its safety during pregnancy is not fully established.

Monitoring Parameters

Patients on Abilify should be regularly monitored for changes in glucose levels, weight, and lipid profile. Periodic assessment of mental status and symptom severity is also crucial. Long-term users should be evaluated for movement disorders.

Storage

Abilify should be stored at room temperature between 15°C to 30°C (59°F to 86°F). Keep away from excess heat and moisture. Ensure proper disposal of expired or unused medication.

Pharmacokinetics

Abilify has an oral bioavailability of around 87%, with a half-life of approximately 75 hours for extensive metabolizers and 146 hours for poor metabolizers. Metabolism primarily occurs in the liver via the cytochrome P450 system, particularly CYP3A4 and CYP2D6. Elimination is mainly through urine and feces.

Efficacy

Clinical trials have shown Abilify to be effective in improving symptoms of schizophrenia, bipolar disorder, and depression. It often demonstrates quicker response times and reduced symptom relapse compared to placebos in controlled studies.

Patient Education

Patients should be informed about the potential side effects, the importance of adhering to the prescribed dosage, and not to suddenly stop the medication without consulting a healthcare provider. Encourage patients to avoid alcohol and illicit drugs while on this medication.

Generic Availability

Generic versions of aripiprazole are available and have been approved by the FDA, ensuring they meet the same standards as the brand name Abilify in terms of quality and therapeutic efficacy.

Innovative Formulations

Abilify MyCite is a unique digital pill that contains a sensor, which tracks if the medication has been ingested. This information can be helpful for patients, caregivers, and healthcare providers in ensuring medication compliance.

Regulatory Status

Abilify has been approved by the U.S. Food and Drug Administration (FDA) for multiple psychiatric conditions. It is subject to regular review and monitoring to ensure ongoing safety and efficacy in clinical use.